Aleafia Health — Q2 FY2023 Earnings Presentation
28 slides from Aleafia Health's earnings presentation, Nov 9, 2022
Slide 1: Q2 Fiscal Year 2023 Earnings Presentation
November 9, 2022 Q2 Fiscal Year 2023 Earnings Presentation AleafiaHealth.com 1
Slide 2: Disclaimer
Disclaimer FORWARD LOOKING INFORMATION Certain statements herein relating to the Company constitute “forward looking information”, within the meaning of applicable securities laws, including without limitation, statements regarding future estimates, business plans and/or objectives, sales programs,
Slide 3: Presenters
Presenters Executive Leadership Tricia Symmes Matt Sale Chief Executive Officer Chief Financial Officer 20+ years as a senior executive in the pharmaceutical, biotech, consumer packaged goods, and 16+ years of increasingly more senior finance executive experience. Deep capital markets, cannabis indu
Slide 4: New Milestone Achievements
New Milestone Achievements Q2 FY2023 Financial Outperformance with Aleafia Delivering Profitability for the First Time as a Branded Cannabis Producer Adjusted EBITDA Profitability Cost Containment Benchmarks International Growth • Adjusted EBITDA profitability • -6% reduction in FTE since Q1 FY2023;
Slide 5: 4 Core Strategic Objectives
4 Core Strategic Objectives Continues to Demonstrate Growth and Leadership Across all Four Strategic Pillars on our Path to Profitability Top 10 Adult-Use Adjusted EBITDA Leadership in Medical Growing International Market Position Profitability • $23 million run-rate net revenue (1) • $12 million ru
Slide 6: Transformation of the Business
Transformation of the Business Robust Growth in Revenue Partially Offset by Higher Excise Duty Burden Net Revenue Breakdown Net Revenue Breakdown (Q3 FY2022 September 30, 2021) (Q2 FY2023 September 30, 2022) Wholesale 20% Adult-Use 53% Medical 27% Revenue +21% Net Revenue +11% $10M Branded Cannabis
Slide 7: Aleafia Health in the News
Aleafia Health in the News First to appear in a major international film festival, unique event offering for consumers, and media coverage in Q2 2022 Key Marketing / PR Features Noon & Night Nitecaps featured as 1st ever CBD / cannabis product in Toronto International Film Festival (TIFF) product su
Slide 8: Business Overview & Performance
Business Overview & Performance Q2 | FY2023 Earnings Presentation
Slide 9: Q2 FY2023 Highlights: Adult-Use Sales Channel
Q2 FY2023 Highlights: Adult-Use Sales Channel Robust Growth in Adult-Use Net Revenue Year over Year Driven by Flagship Divvy Brand Adult-Use Revenue Divvy Entrenchment in Adult-Use Market 31% growth in total revenue over the prior year 14% growth in net revenue over the prior year Top 3 among top 20
Slide 10: Continuing to Capture Adult-Use Share With Third Highest Growth In Sell-Through
Continuing to Capture Adult-Use Share With Third Highest Growth In Sell-Through Retail Sell Through Growth Maintaining close to 90% year over year in BC, AB, SK, and ON Pre-Rolls Flower Q2 2021 3.0% market share in +68% CQGR since listed regions Q1 CY2021 35% QoQ growth in retail sell through (Ontar
Slide 11: Value Segment: Divvy Ranking
Value Segment: Divvy Ranking Demonstrating Leadership Positions in the $750 Million Non-Premium Segment TAM of Value Segment (1) Progress Towards Top 10 Market Share Targets In Ontario (2) Flower + Pre-roll Vapes Concentrates Oils Topicals Market Share Category Market Share Progress Rank Milled Flow
Slide 12: Port Perry 2022 Harvest Update
Port Perry 2022 Harvest Update Continued Improvement in Growing Best Practices Increasing Usable Flower Supply for Adult-Use Branded Products Overall • Average potencies exceed 20% THC • Harvest started sooner than prior year • Flower will be in market in pre-roll and milled product formats by end o
Slide 13: Grimsby Update
Grimsby Update Strategic Decision to Wind Down the Hybrid Greenhouse Facility Strategic Rationale ● Asset Optimization: reviewing fixed assets to maximize long-term profitability ● Greenhouse cultivation facility (approx. 160,000 sq ft) will be wound down ● Third-party sourcing: high-THC flower to s
Slide 14: Q2 FY2023 Highlights: Medical Sales Channel
Q2 FY2023 Highlights: Medical Sales Channel Growth in Product Portfolio and Outreach For Patient Groups Offset Industry Trends and Increase Year-Over-Year Growth in New Markets Medical Net Revenue Driving Growth in Medical ● Increased customer outreach programs with key patient segments and clinics
Slide 15: Q2 FY2023 Highlights: International Sales Channel
Q2 FY2023 Highlights: International Sales Channel Secured New European Partner ● Record quarter for international sales ● Executed purchase order for 1st shipment in November 2022 under new strategic partner ● EU-GACP certified by partner ● Seeing growing demand in Australia ● Reiterate will meet mi
Slide 16: Financial Overview
Financial Overview Q2 | FY2023 Earnings Presentation
Slide 17: Achieved Positive Adjusted EBITDA Profitability
Achieved Positive Adjusted EBITDA Profitability Current Adjusted SG&A Profile Flexible and Scalable to Facilitate Continued Revenue Growth Select Projects Underway to Drive Profitability Milestone Achievement of Adjusted EBITDA Profitability ● Strategic relationships to unlock further flower supply
Slide 18: Significant Cost Rationalizations in Adjusted SG&A to Dramatically Reduce Cash Burn
Significant Cost Rationalizations in Adjusted SG&A to Dramatically Reduce Cash Burn Current Adjusted SG&A Profile Flexible and Scalable to Facilitate Continued Net Revenue Growth Aggressive Cost Rationalizations Driven -38% Reduction in Quarterly Adjusted Economics of Scale SG&A Over the Last 4 Quar
Slide 19: Key Financial Highlights of Q2 FY2023
Key Financial Highlights of Q2 FY2023 Branded Cannabis Net Revenue Across Adult-use, Medical, and International Segments Drives Aleafia Health’s Path to Profitability Total revenue increased by 21% Net revenue increased 11% driven by 23% growth in branded cannabis net revenue Adult-Use • Net revenue
Slide 20: Strong Growth and Adjusted EBITDA Profitability a Catalyst for Potential Valuation Re-Rate
Strong Growth and Adjusted EBITDA Profitability a Catalyst for Potential Valuation Re-Rate Top Quartile Retail Sales Pull through Growth Rates Combined Profitability Provides Opportunity for Robust Shareholder Returns EV / 2023E Net Revenue (2) Leading Key Valuation Metrics ● Top quartile growth rat
Slide 21: Current Capitalization
Current Capitalization Balance Sheet Transformation in Progress; Near-term Liquidity from Receivables Facility and No Near-term Refinancings Required Liquidity to Drive Growth • $1.9 Million Cash on hand (as at September 30, 2022) • $7 Million Receivables Facility ($4.5 million undrawn) Credit Facil
Slide 22: Net Working Capital Optimization
Net Working Capital Optimization Net Working Capital being Optimized to Improve Liquidity and Optimize Returns on Capital Receivables Management Net Working Capital Optimization (1) • Receivables facility to fund A/R growth in sales to four provinces Inventory Management • Right-sized inventory • In
Slide 23: Multi-Pronged Growth Strategy Across Three High Value Pillars
Multi-Pronged Growth Strategy Across Three High Value Pillars Initiatives Underway to Drive Net Revenue Growth Across All Sales Channels for Branded Cannabis Product Portfolio Adult-Use Net Revenue Composition ● Expand high-margin product lineup within Divvy catalogue ● Build consumer engagement pro
Slide 24: Progress Toward FY2023 Targets
Progress Toward FY2023 Targets Ahead of Plan on Adjusted EBITDA Profitability and On-track to Meet FY2023 Net Revenue and Gross Profit Margin Targets1 Net Revenue FY 2023 Progress Toward Targets1 Profitable net revenue growth across all three core sales channels Reduced top end of guidance due to ma
Slide 25: End Remarks
End Remarks Executive Leadership Q2 | FY2023 Earnings Presentation
Slide 26: Q&A
Q&A Q2 | FY2023 Earnings Presentation
Slide 27: Non-IFRS Measures - Adjusted EBITDA
Non-IFRS Measures - Adjusted EBITDA EBITDA is calculated as net income (loss) adding back depreciation and amortization, interest expense, and income taxes expense (recovery Q2 | FY2023 Earnings Presentation Note: See Cautionary Statement Regarding Non-IFRS Measures
Slide 28: Non-IFRS Measures - Adjusted SG&A
Non-IFRS Measures - Adjusted SG&A Q2 | FY2023 Earnings Presentation Note: See Cautionary Statement Regarding Non-IFRS Measures